Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL1706 or QL1604 Combined With Bevacizumab in Advanced Hepatocellular Carcinoma
CTR20222220Phase 2Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2022
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of iparomlimab in hepatocellular carcinoma (HCC), sponsored by Qilu Pharmaceutical. Started Aug 2022; status: completed.
02
Drugs
iparomlimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20222220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222220.